Latest 8-K filings

Dentsply Sirona announced second quarter 2026 financial results, reporting net sales of $898 million and adjusted EPS of $0.52, meeting expectations and reiterating its full-year outlook.

Lyell Immunopharma announced second quarter 2026 financial results and business highlights, detailing advancements in its CAR T-cell therapies for LBCL and mCRC, with approximately $228 million in cash providing runway into Q3 2027.

Senseonics Holdings, Inc. announced record second quarter 2026 revenue of $14.5 million, a 120% year-over-year increase, and raised its full-year revenue and gross margin guidance.

Innovate Corp. announced a significant increase in second quarter 2026 revenue and a swing to net income, driven by robust performance in its Infrastructure segment and strategic financial maneuvers.

Structure Therapeutics reported Q2 2026 financial results, highlighted by the initiation of Phase 3 trials for its oral GLP-1 agonist aleniglipron and a robust cash reserve extending runway through 2028.

OmniAb Inc. announced robust second quarter 2026 financial results, showcasing a substantial increase in revenue and an improved full-year financial outlook driven by strong business momentum and partner program progress.

Astrana Health announced robust second quarter 2026 financial results, showcasing significant year-over-year growth in revenue, net income, and adjusted EBITDA, and raised its full-year adjusted EBITDA guidance.

CarGurus announced strong second-quarter 2026 results, with revenue increasing 13% year-over-year to $251.0 million, alongside an amendment to its credit agreement extending the maturity date.

Relay Therapeutics announced an amendment to its common stock sales agreement, increasing the at-the-market offering program to $462.98 million and reported its second quarter 2026 financial results, including a net loss of $83.7 million.

Westrock Coffee Company announced strong second quarter 2026 results, including an 8.8% increase in net sales and a 38.9% rise in Consolidated Adjusted EBITDA, while reaffirming its full-year financial guidance.

Alarm.com Holdings, Inc. announced robust second quarter 2026 financial results, highlighted by an 11.1% increase in SaaS and license revenue to $188.8 million and an upward revision of its full-year 2026 guidance.

ICU Medical announced strong second quarter 2026 results, exceeding expectations for Infusion Systems and generally meeting them for other segments, leading to an upward revision of its full-year financial guidance.

Once Upon a Farm announced robust second quarter 2026 financial results, showcasing a 42.3% increase in net sales and raising its full-year outlook for both net sales and Adjusted EBITDA.

AVITA Medical reported an 18% year-over-year revenue increase for Q2 2026, raised its full-year revenue guidance, and anticipates achieving cash flow breakeven in Q4 2026.

Definium Therapeutics announced positive Phase 3 Emerge study results for DT120 ODT in MDD, substantial cash reserves, and progress across its GAD and MDD clinical programs.

CytomX Therapeutics reported Q2 2026 financial results, highlighting progress in its Varseta-M program, expansion of its Regeneron collaboration, and strengthening of its leadership team, while also noting increased operating expenses and decreased revenue.

Alector announced its second quarter 2026 financial results, reporting $172.8 million in cash and cash equivalents, sufficient to fund operations through 2027, while detailing progress in its Alector Brain Carrier (ABC) platform and related drug candidates.

AEye announced Q2 2026 results with revenue nearly doubling sequentially and growing nine-fold year-over-year, driven by new commercial deals and expanding verticals.

Axos Financial's August 2026 investor presentation showcases strong Q4 FY26 results, including significant asset and deposit growth, alongside strategic initiatives for continued profitable expansion.

The RealReal announced strong second quarter 2026 results, exceeding outlook with record GMV and significant margin expansion, prompting an increase in full-year financial guidance.

Inogen Inc. announced second quarter 2026 financial results, reporting $95.1 million in revenue and raising full-year adjusted EBITDA guidance to approximately $4.0 million.

Zentalis Pharmaceuticals reports Q2 2026 results, with its lead drug azenosertib showing continued progress in ovarian cancer trials, aiming for accelerated approval.

Silvaco Group announced its second quarter 2026 financial results, highlighting better-than-expected operating results driven by expense management and strategic partnerships with NVIDIA and Dassault Systemes.

Halozyme Therapeutics announced record second quarter 2026 results, exceeding estimates with a 48% year-over-year revenue increase and raising its full-year financial guidance.

Fidus Investment Corporation announced its second quarter 2026 financial results, reporting total investment income of $43.5 million and declaring a total dividend of $0.50 per share for the third quarter.

StepStone Group Inc. announced its first quarter fiscal year 2027 financial results, reporting growth in fee revenues and assets under management, alongside a declared quarterly dividend.

BioLife Solutions announced a 21% year-over-year revenue increase for Q2 2026, alongside a significant acquisition agreement with Repligen expected to close in Q4 2026.

Republic Services announced strong Q2 2026 results, leading to an increase in full-year financial guidance for revenue, adjusted EBITDA, adjusted diluted EPS, and adjusted free cash flow, alongside a dividend increase.

ParkerVision, Inc. reported a reduced net loss for the first half of 2026, but faces ongoing legal proceedings and a decrease in cash reserves.

Cerence AI announced robust third-quarter fiscal year 2026 results, featuring 12% year-over-year revenue growth and the authorization of its first-ever $30 million stock repurchase program.